Association between cannabis and psychosis: Epidemiologic evidence

Biological Psychiatry

Volumn 79, Issue 7, 2016, Pages 549-556

  Gage, Suzanne H ^a   Hickman, Matthew ^a   Zammit, Stanley ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Cannabis; Epidemiology; Longitudinal studies; Marijuana; Psychosis; Schizophrenia

Indexed keywords

CANNABIS; CANNABINOID;

CANNABIS USE; CASE CONTROL STUDY; DISEASE ASSOCIATION; HIGH RISK POPULATION; HUMAN; LONGITUDINAL STUDY; PRIORITY JOURNAL; PSYCHOSIS; PUBLIC HEALTH MESSAGE; REVIEW; CANNABIS ADDICTION; CANNABIS SMOKING; META ANALYSIS (TOPIC); PSYCHOLOGY; PSYCHOSES, SUBSTANCE-INDUCED; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

CANNABINOIDS; CANNABIS; HUMANS; MARIJUANA ABUSE; MARIJUANA SMOKING; META-ANALYSIS AS TOPIC; PSYCHOSES, SUBSTANCE-INDUCED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84941784447     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2015.08.001     Document Type: Review

References (70)

1. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, et al. (2004): The psychotomimetic effects of intravenous delta-9- tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology 29:1558-1572.
2. Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson TR (2007): Metaanalysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 23:17-24.
3. Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jorgensen P (2005): Cannabis-induced psychosis and subsequent schizophreniaspectrum disorders: Follow-up study of 535 incident cases. Br J Psychiatry 187:510-515.
4. Hall W, Degenhardt L (2000): Cannabis use and psychosis: A review of clinical and epidemiological evidence. Aust N Z J Psychiatry 34:26-34.
5. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK (1990): Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264:2511-2518.
6. Semple DM, McIntosh AM, Lawrie SM (2005): Cannabis as a risk factor for psychosis: Systematic review. J Psychopharmacol 19: 187-194.
7. Ferdinand RF, Sondeijker F, van der Ende J, Selten JP, Huizink A, Verhulst FC (2005): Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 100:612-618.
8. Hides L, Lubman DI, Buckby J, Yuen HP, Cosgrave E, Baker K, Yung AR (2009): The association between early cannabis use and psychotic-like experiences in a community adolescent sample. Schizophr Res 112:130-135.
9. Miettunen J, Tormanen S, Murray GK, Jones PB, Maki P, Ebeling H, et al. (2008): Association of cannabis use with prodromal symptoms of psychosis in adolescence. Br J Psychiatry 192:470-471.
10. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007): Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 370: 319-328.
11. Andreasson S, Allebeck P, Engstrom A, Rydberg U (1987): Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2:1483-1486.
12. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G (2002): Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: Historical cohort study. BMJ 325:1199.
13. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE (2002): Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. BMJ 325:1212-1213.
14. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H (2002): Cannabis use and psychosis: A longitudinal population-based study. Am J Epidemiol 156:319-327.
15. Kuepper R, van Os J, Lieb R, Wittchen HU, Hofler M, Henquet C (2011): Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. Br Med J 342:d738.
16. Callaghan RC, Cunningham JK, Allebeck P, Arenovich T, Sajeev G, Remington G, et al. (2012): Methamphetamine use and schizophrenia: A population-based cohort study in California. Am J Psychiatry 169: 389-396.
17. Fergusson DM, Horwood LJ, Ridder EM (2005): Tests of causal linkages between cannabis use and psychotic symptoms. Addiction 100:354-366.
18. Fergusson DM, Horwood LJ, Swain-Campbell NR (2003): Cannabis dependence and psychotic symptoms in young people. Psychol Med 33:15-21.
19. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, van Os J (2005): Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 330:11.
20. Tien AY, Anthony JC (1990): Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences. J Nerv Ment Dis 178:473-480.
21. Wiles NJ, Zammit S, Bebbington P, Singleton N, Meltzer H, Lewis G (2006): Self-reported psychotic symptoms in the general population: Results from the longitudinal study of the British National Psychiatric Morbidity Survey. Br J Psychiatry 188:519-526.
22. Rossler W, Hengartner MP, Angst J, Ajdacic-Gross V (2012): Linking substance use with symptoms of subclinical psychosis in a community cohort over 30 years. Addiction 107:1174-1184.
23. Gage SH, Hickman M, Heron J, Munafo M, Lewis G, Macleod J, Zammit S (2014): Associations of cannabis and cigarette use with psychotic experiences at age 18: Findings from the Avon Longitudinal Study of Parents and Children. Psychol Med 44:3435-3444.
24. Power RA, Verweij KJ, Zuhair M, Montgomery GW, Henders AK, Heath AC, et al. (2014): Genetic predisposition to schizophrenia associated with increased use of cannabis. Mol Psychiatry 19: 1201-1204.
25. McGrath J, Welham J, Scott J, Varghese D, Degenhardt L, Hayatbakhsh MR, et al. (2010): Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry 67:440-447.
26. Giordano GN, Ohlsson H, Sundquist K, Sundquist J, Kendler KS (2015): The association between cannabis abuse and subsequent schizophrenia: A Swedish national co-relative control study. Psychol Med 45:407-414.
27. Morgan CJ, Curran HV (2008): Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 192:306-307.
28. Morgan CJ, Gardener C, Schafer G, Swan S, Demarchi C, Freeman TP, et al. (2012): Subchronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med 42:391-400.
29. Iseger TA, Bossong MG (2015): A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res 162: 153-161.
30. Allott K, Chanen A, Yuen HP (2006): Attrition bias in longitudinal research involving adolescent psychiatric outpatients. J Nerv Ment Dis 194:958-961.
31. Fischer EH, Dornelas EA, Goethe JW (2001): Characteristics of people lost to attrition in psychiatric follow-up studies. J Nerv Ment Dis 189: 49-55.
32. Rothman K, Greenland S, Lash TL (2008): Modern Epidemiology, 3rd ed. Philadelphia: Lippincott Williams & Wilkins.
33. Rubino T, Parolaro D (2008): Long lasting consequences of cannabis exposure in adolescence. Mol Cell Endocrinol 286:S108-S113.
34. Trezza V, Cuomo V, Vanderschuren LJ (2008): Cannabis and the developing brain: Insights from behavior. Eur J Pharmacol 585: 441-452.
35. Chadwick B, Miller ML, Hurd YL (2013): Cannabis use during adolescent development: Susceptibility to psychiatric illness. Front Psychiatry 4:129.
36. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, et al. (2005): Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol- O-methyltransferase gene: Longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57:1117-1127.
37. Zammit S, Owen MJ, Lewis G (2010): Misconceptions about geneenvironment interactions in psychiatry. Evid Based Ment Health 13: 65-68.
38. Zammit S, Wiles N, Lewis G (2010): The study of gene environment interactions in psychiatry: Limited gains at a substantial cost? Psychol Med 40:711-716.
39. van Winkel R & Genetic Risk and Outcome of Psychosis (GROUP) Investigators. (2011): Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: Sibling analysis and proband follow-up. Arch Gen Psychiatry 68:148-157.
40. Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A, et al. (2012): Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry 72: 811-816.
41. Duncan LE, Keller MC (2011): A critical review of the first 10 years of candidate gene-by-environment interaction research in psychiatry. Am J Psychiatry 168:1041-1049.
42. Cougnard A, Marcelis M, Myin-Germeys I, De Graaf R, Vollebergh W, Krabbendam L, et al. (2007): Does normal developmental expression of psychosis combine with environmental risk to cause persistence of psychosis? A psychosis proneness-persistence model. Psychol Med 37:513-527.
43. Harley M, Kelleher I, Clarke M, Lynch F, Arseneault L, Connor D, et al. (2010): Cannabis use and childhood trauma interact additively to increase the risk of psychotic symptoms in adolescence. Psychol Med 40:1627-1634.
44. Houston JE, Murphy J, Adamson G, Stringer M, Shevlin M (2008): Childhood sexual abuse, early cannabis use, and psychosis: Testing an interaction model based on the National Comorbidity Survey. Schizophr Bull 34:580-585.
45. Greenland S, Lash TL, Rothman KJ (2008): Concepts of Interaction In Modern Epidemiology. Philadelphia: Lippincott Williams and Wilkins.
46. Zammit S, Lewis G, Dalman C, Allebeck P (2010): Examining interactions between risk factors for psychosis. Br J Psychiatry 197: 207-211.
47. Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, et al. (2013): Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 27:19-27.
48. Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, et al. (2015): Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: A casecontrol study. Lancet Psychiatry 2:233-238.
49. Gage SH, Munafo MR, MacLeod J, Hickman M, Davey Smith G (2015): Cannabis and psychosis: A problem of skunk, or extremes? Lancet Psychiatry 2:380.
50. Hardwick S, King L (2008): Home Office Cannabis Potency Study 2008. In: Office H, editor. Home Office Cannabis Potency Study 2008. St Albans, UK: Home Office Scientific Development Branch.
51. Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS, et al. (2010): Potency trends of Delta9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 55:1209-1217.
52. King L, Carpentier C, Griffiths P (2004): EMCDDA Insights: An overview of cannabis potency in Europe. Villa Louvigny, Luxembourg: European Monitoring Centre for Drugs and Drug Addiction.
53. Frisher M, Crome I, Macleod J, Millson D, Croft P (2005): Substance misuse and psychiatric illness: Prospective observational study using the general practice research database. J Epidemiol Community Health 59:847-850.
54. van Amsterdam J, Brunt T, van den Brink W (2015): The adverse health effects of synthetic cannabinoids with emphasis on psychosislike effects. J Psychopharmacol 29:254-263.
55. Kuepper R, Morrison PD, van Os J, Murray RM, Kenis G, Henquet C (2010): Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. Schizophr Res 121:107-117.
56. Price C, Hemmingsson T, Lewis G, Zammit S, Allebeck P (2009): Cannabis and suicide: Longitudinal study. Br J Psychiatry 195:492-497.
57. Gage SH, Hickman M, Heron J, Munafo MR, Lewis G, MacLeod J, Zammit S (2015): Association of cannabis and cigarette use with depression and anxiety at age 18: Findings from the Avon Longitudinal Study of Parents and Children. PLoS One 10:e0122896.
58. Ajdacic-Gross V, Landolt K, Angst J, Gamma A, Merikangas KR, Gutzwiller F, Rössler W (2009): Adult versus adolescent onset of smoking: How are mood disorders and other risk factors involved? Addiction 104:1411-1419.
59. Boydell J, Van Os J, Lambri M, Castle D, Allardyce J, McCreadie RG, Murray RM (2003): Incidence of schizophrenia in south-east London between 1965 and 1997. Br J Psychiatry 182:45-49.
60. Breslau J, Aguilar-Gaxiola S, Kendler KS, Su M, Williams D, Kessler RC (2006): Specifying race-ethnic differences in risk for psychiatric disorder in a USA national sample. Psychol Med 36:57-68.
61. Frisher M, Crome I, Martino O, Croft P (2009): Assessing the impact of cannabis use on trends in diagnosed schizophrenia in the United Kingdom from 1996 to 2005. Schizophr Res 113:123-128.
62. Davey Smith G, Ebrahim S (2002): Data dredging, bias, or confounding. BMJ 325:1437-1438.
63. Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, et al. (2012): Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A 109: E2657-E2664.
64. Gage SH, Munafo M, Davey Smith G (2016): Causal inference in developmental origins of health and disease (DOHaD) research (in press). Annu Rev Psychol 67:567-585.
65. Brion MJ, Lawlor DA, Matijasevich A, Horta B, Anselmi L, Araujo CL, et al. (2011): What are the causal effects of breastfeeding on IQ, obesity and blood pressure? Evidence from comparing high-income with middle-income cohorts. Int J Epidemiol 40:670-680.
66. Gage SH, Davey Smith G, Zammit S, Hickman M, Munafo MR (2013): Using Mendelian randomisation to infer causality in depression and anxiety research. Depress Anxiety 30:1185-1193.
67. Schizophrenia Working Group of the Psychiatric Genomics Consortium. (2014): Biological insights from 108 schizophrenia-associated genetic loci. Nature 511:421-427.
68. Hickman M, Vickerman P, Macleod J, Lewis G, Zammit S, Kirkbride J, Jones P (2009): If cannabis caused schizophrenia-how many cannabis users may need to be prevented in order to prevent one case of schizophrenia? England and Wales calculations. Addiction 104: 1856-1861.
69. Danovitch I, Gorelick DA (2012): State of the art treatments for cannabis dependence. Psychiatr Clin North Am 35:309-326.
70. Campbell R, Starkey F, Holliday J, Audrey S, Bloor M, Parry-Langdon N, et al. (2008): An informal school-based peer-led intervention for smoking prevention in adolescence (ASSIST): A cluster randomised trial. Lancet 371:1595-1602.